FI20010922A - Uusia vektoreita - Google Patents

Uusia vektoreita Download PDF

Info

Publication number
FI20010922A
FI20010922A FI20010922A FI20010922A FI20010922A FI 20010922 A FI20010922 A FI 20010922A FI 20010922 A FI20010922 A FI 20010922A FI 20010922 A FI20010922 A FI 20010922A FI 20010922 A FI20010922 A FI 20010922A
Authority
FI
Finland
Prior art keywords
new vectors
vectors
new
Prior art date
Application number
FI20010922A
Other languages
English (en)
Swedish (sv)
Other versions
FI116851B (fi
FI20010922A0 (fi
Inventor
Kai Krohn
Vesna Blazevic
Marja Taehtinen
Mart Ustav
Urve Toots
Andres Maennik
Original Assignee
Fit Biotech Oyj Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fit Biotech Oyj Plc filed Critical Fit Biotech Oyj Plc
Publication of FI20010922A0 publication Critical patent/FI20010922A0/fi
Priority to FI20010922A priority Critical patent/FI116851B/fi
Priority to IL15873002A priority patent/IL158730A0/xx
Priority to SI200230827T priority patent/SI1390516T1/sl
Priority to CA2446260A priority patent/CA2446260C/en
Priority to NZ529327A priority patent/NZ529327A/en
Priority to ES02722308T priority patent/ES2324095T3/es
Priority to PL367126A priority patent/PL206097B1/pl
Priority to JP2002587618A priority patent/JP5016779B2/ja
Priority to US10/476,615 priority patent/US7510718B2/en
Priority to HU0304053A priority patent/HU227667B1/hu
Priority to DK02722308T priority patent/DK1390516T3/da
Priority to BRPI0209416A priority patent/BRPI0209416A8/pt
Priority to AT02722308T priority patent/ATE426035T1/de
Priority to EP02722308A priority patent/EP1390516B1/en
Priority to APAP/P/2003/002914A priority patent/AP2368A/en
Priority to US10/138,098 priority patent/US7498314B2/en
Priority to PCT/FI2002/000379 priority patent/WO2002090558A1/en
Priority to PT02722308T priority patent/PT1390516E/pt
Priority to SK1469-2003A priority patent/SK287471B6/sk
Priority to CNB028133048A priority patent/CN100430482C/zh
Priority to DE60231613T priority patent/DE60231613D1/de
Priority to EA200301207A priority patent/EA009388B1/ru
Priority to KR1020037014336A priority patent/KR100873109B1/ko
Priority to CZ20033201A priority patent/CZ301691B6/cs
Priority to AU2002253198A priority patent/AU2002253198B2/en
Priority to EEP200300483A priority patent/EE05691B1/xx
Priority to MXPA03009978A priority patent/MXPA03009978A/es
Publication of FI20010922A publication Critical patent/FI20010922A/fi
Priority to ZA2003/08390A priority patent/ZA200308390B/en
Priority to IL158730A priority patent/IL158730A/en
Priority to HK04106222.3A priority patent/HK1063486A1/xx
Application granted granted Critical
Publication of FI116851B publication Critical patent/FI116851B/fi
Priority to US12/360,615 priority patent/US20090252707A1/en
Priority to CY20091100588T priority patent/CY1114047T1/el
Priority to JP2009191744A priority patent/JP2010042000A/ja
Priority to US14/153,576 priority patent/US9725486B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI20010922A 2001-05-03 2001-05-03 Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita FI116851B (fi)

Priority Applications (34)

Application Number Priority Date Filing Date Title
FI20010922A FI116851B (fi) 2001-05-03 2001-05-03 Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
PCT/FI2002/000379 WO2002090558A1 (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
CNB028133048A CN100430482C (zh) 2001-05-03 2002-05-03 新的表达载体及其应用
PT02722308T PT1390516E (pt) 2001-05-03 2002-05-03 Novos vectores de expressão e uso dos mesmos
SI200230827T SI1390516T1 (sl) 2001-05-03 2002-05-03 Novi ekspresijski vektorji in njihova uporaba
ES02722308T ES2324095T3 (es) 2001-05-03 2002-05-03 Vectores de expresion novedosos y usos de los mismos.
PL367126A PL206097B1 (pl) 2001-05-03 2002-05-03 Wektor ekspresyjny, jego zastosowanie, sposób wytwarzania tego wektora, komórka gospodarza, kompozycja farmaceutyczna, szczepionka DNA, genowy czynnik terapeutyczny oraz sposób wytwarzania szczepionki DNA
JP2002587618A JP5016779B2 (ja) 2001-05-03 2002-05-03 発現ベクターおよびその使用方法
US10/476,615 US7510718B2 (en) 2001-05-03 2002-05-03 Expression vectors and uses thereof
HU0304053A HU227667B1 (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
DK02722308T DK1390516T3 (da) 2001-05-03 2002-05-03 Hidtil ukendte ekspressionsvektorer og anvendelser deraf
BRPI0209416A BRPI0209416A8 (pt) 2001-05-03 2002-05-03 novos vetores de expressão e uso dos mesmos
AT02722308T ATE426035T1 (de) 2001-05-03 2002-05-03 Neue expressionsvektoren und deren verwendungen
EP02722308A EP1390516B1 (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
APAP/P/2003/002914A AP2368A (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof.
US10/138,098 US7498314B2 (en) 2001-05-03 2002-05-03 Expression vectors and uses thereof
IL15873002A IL158730A0 (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
CA2446260A CA2446260C (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
NZ529327A NZ529327A (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
SK1469-2003A SK287471B6 (sk) 2001-05-03 2002-05-03 Expresné vektory a ich použitie
DE60231613T DE60231613D1 (de) 2001-05-03 2002-05-03 Neue expressionsvektoren und deren verwendungen
EA200301207A EA009388B1 (ru) 2001-05-03 2002-05-03 Векторы экспрессии и способы их применения
KR1020037014336A KR100873109B1 (ko) 2001-05-03 2002-05-03 신규 발현 벡터 및 이의 용도
CZ20033201A CZ301691B6 (cs) 2001-05-03 2002-05-03 Nové expresní vektory a jejich použití
AU2002253198A AU2002253198B2 (en) 2001-05-03 2002-05-03 Novel expression vectors and uses thereof
EEP200300483A EE05691B1 (et) 2001-05-03 2002-05-03 Ekspressioonivektorid ja nende rakendused
MXPA03009978A MXPA03009978A (es) 2001-05-03 2002-05-03 Vectores de expresion novedosos y usos de los mismos.
ZA2003/08390A ZA200308390B (en) 2001-05-03 2003-10-28 Novel expression vectors and uses thereof
IL158730A IL158730A (en) 2001-05-03 2003-11-03 Expression vectors based upon the e2 protein of the bovine papilloma virus type 1, uses thereof and methods for the preparation thereof
HK04106222.3A HK1063486A1 (en) 2001-05-03 2004-08-19 Novel expression vectors and uses thereof
US12/360,615 US20090252707A1 (en) 2001-05-03 2009-01-27 Novel expression vectors and uses thereof
CY20091100588T CY1114047T1 (el) 2001-05-03 2009-06-02 Νεοι φορεις εκφρασης και χρησεις αυτων
JP2009191744A JP2010042000A (ja) 2001-05-03 2009-08-21 発現ベクターおよびその使用方法
US14/153,576 US9725486B2 (en) 2001-05-03 2014-01-13 Methods of treating HIV diseases using novel expression vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010922 2001-05-03
FI20010922A FI116851B (fi) 2001-05-03 2001-05-03 Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita

Publications (3)

Publication Number Publication Date
FI20010922A0 FI20010922A0 (fi) 2001-05-03
FI20010922A true FI20010922A (fi) 2002-11-04
FI116851B FI116851B (fi) 2006-03-15

Family

ID=8561113

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20010922A FI116851B (fi) 2001-05-03 2001-05-03 Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita

Country Status (7)

Country Link
US (4) US7510718B2 (fi)
JP (1) JP2010042000A (fi)
KR (1) KR100873109B1 (fi)
CY (1) CY1114047T1 (fi)
FI (1) FI116851B (fi)
PT (1) PT1390516E (fi)
ZA (1) ZA200308390B (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000330989A (ja) * 1999-05-21 2000-11-30 Fujitsu Ltd 構造化文書作成方法および構造化文書を記録したコンピュータ読取可能な記録媒体
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7312202B2 (en) * 2003-02-18 2007-12-25 Board Of Regents, The University Of Texas System Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy
US8377653B2 (en) * 2005-02-11 2013-02-19 Icosagen Cell Factory Oü Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
US7790446B2 (en) * 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
TW200745332A (en) * 2005-07-21 2007-12-16 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
EP2397855A3 (en) 2006-03-14 2012-03-14 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
US7479550B2 (en) * 2006-06-02 2009-01-20 The Board Of Regents Of The University Of Texas System Amyloid β gene vaccines
RU2010152562A (ru) * 2008-05-23 2012-06-27 Фит Байотек Ой (Fi) Векторы экспрессии, кодирующие репликазу альфавируса, и их применение в качестве иммунологического адьюванта
NZ594896A (en) * 2009-04-17 2013-07-26 Transgene Sa Biomarker for monitoring patients
WO2011005525A2 (en) 2009-06-22 2011-01-13 Health Research Inc. Prodrug anti-cancer therapy
WO2011053699A1 (en) * 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
US8927218B2 (en) 2011-06-27 2015-01-06 Flir Systems, Inc. Methods and compositions for segregating target nucleic acid from mixed nucleic acid samples
WO2013003376A2 (en) 2011-06-27 2013-01-03 Flir Systems, Inc. Methods and compositions for segregating target nucleic acid from mixed nucleic acid samples
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CN108595788A (zh) * 2018-04-05 2018-09-28 西北工业大学 一种基于模态多重网格的流场加速收敛方法
US11685936B2 (en) * 2018-10-18 2023-06-27 Icosagen Cell Factory Oü Platform for developing stable mammalian cell lines
AU2020368656A1 (en) * 2019-10-16 2022-04-21 Janssen Vaccines & Prevention B.V. Vaccine product

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
TW201794B (fi) * 1991-05-03 1993-03-11 American Cyanamid Co
JPH06510524A (ja) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット 免疫原性タンパク質をコードする遺伝子の標的への配達
JPH06510278A (ja) 1991-06-05 1994-11-17 ユニバーシティ オブ コネチカット 分泌タンパク質をコードする遺伝子の標的への配達
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
AU7353494A (en) * 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US6479279B2 (en) * 1995-12-29 2002-11-12 Estonian Biocentre Episomal vectors and uses thereof
EP0870047B1 (en) 1995-12-29 2008-08-06 FIT Biotech Oyj Plc Episomal vector and uses thereof
DE19617851A1 (de) * 1996-05-03 1997-11-13 Hoechst Ag Nukleinsäurekonstrukte mit Genen kodierend für Transportsignale
WO1998002548A2 (en) 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Infectious papillomavirus pseudoviral particles
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
US20020103145A1 (en) * 1999-05-19 2002-08-01 Adrian Bot Immunization of infants
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6951928B1 (en) * 1997-10-02 2005-10-04 National Public Health Institute Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)
FI105105B (fi) 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
EP1115853A2 (en) * 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
AU1084901A (en) * 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita

Also Published As

Publication number Publication date
KR100873109B1 (ko) 2008-12-09
CY1114047T1 (el) 2016-07-27
ZA200308390B (en) 2005-04-26
US20050026137A1 (en) 2005-02-03
PT1390516E (pt) 2009-06-25
JP2010042000A (ja) 2010-02-25
US7498314B2 (en) 2009-03-03
US7510718B2 (en) 2009-03-31
KR20040010635A (ko) 2004-01-31
US20090252707A1 (en) 2009-10-08
US20140234361A1 (en) 2014-08-21
FI116851B (fi) 2006-03-15
FI20010922A0 (fi) 2001-05-03
US20030129169A1 (en) 2003-07-10
US9725486B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
DE50204184D1 (de) Espressobrüheinrichtung
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50208022D1 (de) Wischblatt
DE50206021D1 (de) Schlauchklemme
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50204386D1 (de) Kreuztransducer
DE50209238D1 (de) Kugelgelenk
ATE335486T1 (de) Hydrazono-malonitrile
DE1319930T1 (de) Coriolismassendurchflussmesser
FI20010922A (fi) Uusia vektoreita
NO20014597D0 (no) Fremgangsmåte
DE50204551D1 (de) Kugelgelenk
DE50208372D1 (de) Schrankaufhängevorrichtung
DE50203412D1 (de) Schwenkkolbenverdränger
DE50203984D1 (de) Kugelgelenk
DE50204794D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DE50208029D1 (de) Kugelgelenk
DE50203093D1 (de) Losradlager
ATE319694T1 (de) Phenylalkyne
DE50209293D1 (de) Amidpolymermasse
ATA18372001A (de) Gelenksbolzenbaueinheit
DE50209386D1 (de) Kugelgelenk
DE50202088D1 (de) Garmodulsystem

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116851

Country of ref document: FI

MA Patent expired